UPC

Universe Pharmaceuticals INC

$1.55

-3.13%

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China. The company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. It also provides guben yanling, shenrong weisheng, and quanlu pill; yangxue danggui and qiangli pipa syrup; wuzi yanzong oral, fengtong medicinal, shenrong medicinal, qishe medicinal, fengshitong medicinal, and shiquan dabu medicinal liquor; paracetamol granule for children; and isatis root granule. In addition, the company distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. It primarily serves pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is headquartered in Ji'An, China.

Source: Yahoo Finance
Q-Score46/ 100
Market Cap$7.8M
P/E—
Dividend Yield0.00%
52-Week Range—
Next Earnings—
Analysts—
Beta0.72
AI summary

Price & performance

1M-17.4%
3M-13.6%
YTD-5.5%
1Y-27.9%
52-week range—
Beta0.72
Full chart and returns against a benchmark

Q-Score

46/ 100

Quality against peers; 50 is the peer median.

Growth17
Risk21
Performance56
Valuation96
Profitability45
Leverage44
Sentiment—
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$17.9B-22.4%
Net income—
Net margin—
Historical fundamentals

Red flags in filings

1active red flag
Material weakness in controlsJan 29, 2026
Filings, findings and the timeline

Revenue exposure

Regions, segments, customers and suppliers

Valuation

UPCIndustryP/E—35.25P/S0.002.74EV/EBITDA—16.35P/B0.002.46PEG—0.87
Dividend yield0.00%
Every valuation metric